
    
      This study will be a single center, randomized, open-label, 2 arm study to evaluate the
      effects of EE/norgestimate, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy
      female subjects when EE/norgestimate is administered simultaneously with lomitapide and when
      administration is separated by 12 hours.
    
  